• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    7/3/25 5:03:48 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care
    Get the next $OTRK alert in real time by email
    cats-20250627
    0001136174FALSE00011361742025-06-272025-06-27

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  June 27, 2025

    Ontrak, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3193288-0464853
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)

    333 S. E. 2nd Avenue, Suite 2000, Miami, FL 33131
    (Address of principal executive offices) (Zip Code)

    Registrant’s telephone number, including area code   (310) 444-4300


    (Former name or former address, if changed since last report.)

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.0001 par valueOTRK
    The NASDAQ Capital Market

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐






    Item 1.01 Entry into a Material Definitive Agreement.

    The information regarding the Purchase Agreement, the Prefunded Warrants, the Warrants and the Placement Agency Agreement (each as defined in Item 8.01 below) and the lock-up agreements described in Item 8.01 below is incorporated by reference into this Item 1.01.

    Item 8.01     Other Events.

    On June 30, 2025, Ontrak, Inc., a Delaware corporation (the “Company,” “we,” “us” or “our”), completed a public offering (the “Offering”) of: (i) 2,366,665 shares (the “Shares”) of its common stock, par value $0.0001 per share; (ii) 4,300,002 prefunded warrants (the “Prefunded Warrants”) to purchase 4,300,002 shares of its common stock; and (iii) 26,666,668 warrants (the “Warrants”) to purchase 26,666,668 shares of its common stock. Each Share and Prefunded Warrant was sold with four Warrants, each exercisable to purchase one share of our common stock. The offering price of each Share and four accompanying Warrants was $0.60, and the offering price of each Prefunded Warrant and four accompanying Warrants was $0.5999. We received net proceeds of approximately $3.24 million from the Offering, after deducting the estimated offering expenses payable by us, including the fees we paid to the placement agent for the offering described below. We intend to use the net proceeds from the Offering for working capital and general corporate purposes.

    The Shares, Prefunded Warrants, and Warrants, and the shares of our common stock issuable upon exercise of the Prefunded Warrants and Warrants, were offered pursuant to our Registration Statement on Form S-1 (File No. 333-288099), as amended, which was declared effective by the Securities and Exchange Commission on June 26, 2025.

    On June 27, 2025, we issued a press release announcing the pricing of the Offering, a copy of which is furnished as an exhibit to this report.

    Purchase Agreement

    In connection with the Offering, we entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors on June 27, 2025. The Purchase Agreement contains customary representations, warranties, covenants and agreements of the parties. The representations, warranties and covenants in the Purchase Agreement were made only for the purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by such parties. Under the terms of the Purchase Agreement, we agreed for a period of 180 days from June 30, 2025 (the “Closing Date”), subject to certain exceptions, not to: (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of our common stock or common stock equivalents; (ii) file any registration statement other than the prospectus for the Offering; or (iii) amend, modify or waive the terms of any securities outstanding on June 27, 2025, provided that after 90 days following the Closing Date, we may issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents so long as: (a) the price per share of common stock is at least $0.60; and/or (b) the conversion price, exercise price, or exchange rate per share of common stock underlying any common stock equivalent is at least $0.60. In addition, from the date of the Purchase Agreement until 180 days following the Closing Date, subject to certain exceptions, we are prohibited from effecting or entering into an agreement to effect any issuance of common stock or common stock equivalents involving a Variable Rate Transaction (as defined in the Purchase Agreement).

    Prefunded Warrants

    The Prefunded Warrants are immediately exercisable and may be exercised at an exercise price of $0.0001 per share of Common Stock at any time until all of the Prefunded Warrants are exercised in full.

    Warrants

    Exercisability, Duration, Exercise Price and Form

    Each Warrant has an initial exercise price of $0.60 per share. The Warrants are not exercisable unless and until stockholder approval is obtained. Assuming stockholder approval is obtained, the Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder’s Warrants to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days’ prior notice
    1


    from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. Each warrant may be exercised at any time following the date of the stockholder approval described above and will expire five years from such date.

    Warrant Adjustment Provisions

    In addition to customary adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock, the exercise price of the Warrants and the number of shares of common stock issuable upon exercise thereof are subject to adjustment upon the occurrence of the events described below.

    •Adjustment for Dilutive Issuances. If while the Warrants are outstanding, we issue or sell, or are deemed to have issued or sold, any common stock and/or common stock equivalents, other than in connection with certain exempt issuances, for a consideration per share less than the exercise price in effect immediately prior to such issuance or sale or deemed issuance or sale, then simultaneously with such issuance or sale or deemed issuance or sale, the exercise price of the Warrants then in effect will be reduced to the consideration per share at which the common stock or common stock equivalents were issued or sold or deemed issued or sold.

    •Alternative Exercise Price Following Certain Issuances. If we issue or sell, or enter into any agreement to issue or sell, any common stock, common stock equivalents, or rights, warrants or options to purchase shares of our capital stock or common stock equivalents that are issuable or convertible into or exchangeable or exercisable for shares of common stock at a price which varies or may vary with the market price of our common stock, each Warrant holder will have the right, in its sole discretion, to substitute the variable price for the exercise price of their Warrant.

    •Adjustment for Stock Combination Events. In the event of a stock dividend, stock split, reorganization or similar event affecting our common stock (a “Stock Combination Event”), if the Event Market Price (as defined below) is less than the exercise price then in effect (after giving effect to customary adjustments thereto as a result of the event), then on the fifth trading day immediately following the Stock Combination Event, the exercise price will be reduced to the Event Market Price, subject to certain limitations. “Event Market Price” means, with respect to any Stock Combination Event, the lowest volume weighted average price during the period commencing five consecutive trading days immediately preceding the Stock Combination Event Date and ending five consecutive trading days immediately after the Stock Combination Event Date.

    •Floor Price. In no event will the exercise per share of common stock be reduced to less than $0.19, which $0.19 is subject to customary adjustments in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock.

    •Adjustment to Number of Shares Issuable Upon Exercise. Simultaneously with any adjustment to the exercise price of the Warrants, the number of shares of common stock issuable upon exercise of the Warrants will be increased or decreased proportionally, such that the aggregate exercise price of the Warrants, after taking into account the adjustment in the exercise price, will be equal to the aggregate exercise price before the adjustment in the exercise price.

    In the event of a fundamental transaction, as described in the Warrant, and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the warrants will be entitled to receive upon exercise thereof the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction, other than one in which a successor entity that is a publicly traded corporation (whose stock is quoted or listed for trading on a national securities exchange, including, but not limited to, the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market) assumes the Warrants such that the Warrants will be exercisable for the publicly traded common stock of such successor entity. Additionally, as more fully described in the Warrants, at the option of the holder thereof, the holder can receive consideration in the same type and form of an amount equal to the Black Scholes value (as defined in the Warrants) of such unexercised Warrants on the date of consummation of such transaction.



    2


    Placement Agency Agreement

    In connection with the Offering, on June 27, 2025, we entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), as the exclusive placement agent for the Offering, pursuant to which we paid the Placement Agent a cash fee of 7% of the aggregate gross proceeds raised in the Offering, plus reimbursement of certain expenses and legal fees up to $125,000.

    Lock-Up Agreements

    On June 27, 2025, in connection with the Offering, each of our executive officers and directors and Terren Peizer, Chairman of Acuitas Capital LLC, entered into customary lock-up agreements pursuant to which such parties agreed, subject to certain exceptions, not to dispose of any shares of our common stock or securities convertible into or exchangeable for shares of our common stock during the period from June 27, 2025 continuing through the six months after the closing of the Offering.

    The foregoing descriptions of the Purchase Agreement, the Prefunded Warrants, the Warrants, the Placement Agency Agreement, and the lock-up agreements are not complete and are qualified in their entirety by reference to the full text of such agreements, copies or forms of which are filed as exhibits to this report and are incorporated by reference herein.


    Item 9.01    Financial Statements and Exhibits.
    (d)    Exhibits.

    Exhibit No.
    Description
    4.1
    Form of Prefunded Warrant
    4.2
    Form of Warrant
    10.1
    Placement Agency Agreement, dated as of June 27, 2025, by and between Ontrak, Inc. and Roth Capital Partners, LLC
    10.2
    Form of Purchase Agreement
    10.3
    Form of Lock-up Agreement
    99.1
    Press released dated June 27, 2025
    104Cover Page Interactive Data File (formatted as Inline XBRL)

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Ontrak, Inc.
    Date: July 3, 2025By:/s/ James J. Park
    James J. Park
    Chief Financial Officer
    3
    Get the next $OTRK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OTRK

    DatePrice TargetRatingAnalyst
    12/5/2023$4.00Buy
    ROTH MKM
    3/9/2022$13.00 → $2.50Hold
    Canaccord Genuity
    3/9/2022$11.00 → $2.00Sector Perform
    RBC Capital
    8/20/2021$35.00 → $9.00Market Perform → Underperform
    Cowen & Co.
    8/20/2021$15.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $OTRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ontrak Health Announces Pricing of $4 Million Public Offering

      Ontrak, Inc. (NASDAQ:OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, today announced the pricing of a public offering of 6,666,667 shares of its common stock (or pre-funded warrants in lieu thereof) and 26,666,668 warrants to purchase up to 26,666,668 shares of its common stock at a combined public offering price of $0.60 per share of common stock and accompanying warrants or at a combined public offering price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-fund

      6/27/25 8:30:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health Announces Expansion of Engage Solution for Sentara Health Plans Self-funded Employer Customers

      Ontrak, Inc. (NASDAQ:OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, today announced an expanded partnership with Sentara Health Plans to offer Ontrak's Engage Solution to employer sponsored customers in the Commonwealth of Virginia. Sentara Health Plans is the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system that provides health plan coverage to one million members in Virginia and Florida. Sentara offers programs to support members with chronic illnesses, customized wellness programs, and integrated clinical and behavioral health services—all to help members improve their heal

      6/24/25 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    SEC Filings

    See more
    • Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      7/3/25 5:03:48 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      6/30/25 5:24:52 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 424B5 filed by Ontrak Inc.

      424B5 - Ontrak, Inc. (0001136174) (Filer)

      6/30/25 10:00:23 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Peizer Terren S exercised 500,000 in-the-money shares at a strike of $0.00 (SEC Form 4)

      4 - Ontrak, Inc. (0001136174) (Issuer)

      6/24/25 6:32:14 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Large owner Peizer Terren S

      4 - Ontrak, Inc. (0001136174) (Issuer)

      6/23/25 8:06:38 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Park James J converted options into 4 shares and covered exercise/tax liability with 1 shares, increasing direct ownership by 33% to 12 units (SEC Form 4)

      4 - Ontrak, Inc. (0001136174) (Issuer)

      6/17/25 5:33:52 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Ontrak with a new price target

      ROTH MKM initiated coverage of Ontrak with a rating of Buy and set a new price target of $4.00

      12/5/23 8:03:01 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Canaccord Genuity reiterated coverage on Ontrak with a new price target

      Canaccord Genuity reiterated coverage of Ontrak with a rating of Hold and set a new price target of $2.50 from $13.00 previously

      3/9/22 9:09:19 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital reiterated coverage on Ontrak with a new price target

      RBC Capital reiterated coverage of Ontrak with a rating of Sector Perform and set a new price target of $2.00 from $11.00 previously

      3/9/22 7:43:55 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Ontrak Names James Messina to its Board of Directors

      Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of James Messina as a non-Executive Director to its board. Mr. Messina is a Co-Founder and General Partner of Seattle Hill Ventures and x4 Capital Partners, which invest in, and support, startup ventures by providing business development, marketing, operating and technology support. Previously, Mr. Messina was the Executive Vice President and Chief Operating Officer for Premera Blue Cross ("Premera"). He was responsible for effectively servicing the needs of Premera's customers with oversight of all operational functions, from customer serv

      8/30/22 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Names Dr. Robert Accordino Chief Medical Officer

      Mental Healthcare Leader and Harvard Medical School Faculty Member Joins Ontrak Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Dr. Robert Accordino as Ontrak's Chief Medical Officer, effective September 27, 2021. Dr. Accordino joins Ontrak from Quartet Health where he served as the company's most senior clinician and Chief Mental Health Officer. He practices psychiatry and is on the faculty of Harvard Medical School and Massachusetts General Hospital. Dr. Accordino will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "Dr. Accordino's reputation in

      9/9/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Arik Hill Joins Ontrak as Chief Information Officer

      Former Accenture and KPMG Healthcare Expert Brings Proven Leadership Experience In Behavioral Health Digital Transformation Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Arik Hill as Ontrak's first Chief Information Officer, effective August 30, 2021. Mr. Hill will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "As Chief Information Officer at The New York Foundling, a fast growing organization that collaborates with over 250,000 behavioral healthcare partners across the country, Arik led the development of digital platforms and applications th

      8/12/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Financials

    Live finance-specific insights

    See more
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

      5/19/25 4:30:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2024 Fourth Quarter Financial Results on April 14, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the fourth quarter 2024 on Monday, April 14, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/delivering-a-healthier-future-for-all/presentations-events/. Participants interested in dialing in to the conference call are requested to register a day in advance or

      4/10/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

      SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

      11/14/24 4:24:03 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      10/3/24 6:37:08 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      8/30/24 5:15:15 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care